Ben-Shachar D, Youdim M B
Rappaport Family Research Institute, Department of Pharmacology, Faculty of Medicine, Technion, Haifa, Israel.
J Neural Transm Suppl. 1990;29:251-8. doi: 10.1007/978-3-7091-9050-0_24.
The recent studies on the chemical pathology of Parkinson's disease show selective increases of iron and lipid peroxidation and decreased glutathione (GSH) oxidizing capacity in the substantia nigra (SN). These changes are indicative of oxidative stress, possibly due to the accumulation of iron in the SN. It is the melaninized dopamine neurons that are vunerable to degeneration. The investigation of the interaction of iron with dopamine melanin demonstrates the presence of two relatively high affinity binding sites for 59Fe3+ on dopamine melanin. Interaction of Fe3+ with dopamine melanin results in potentiation of lipid peroxidation of rat cerebral cortex as compared to that induced by Fe3+. Only compounds with the ability to chelate iron are able to inhibit the binding of Fe3+ to melanin and the resultant lipid peroxidation. Therapeutic use of iron chelators, with the ability of crossing the blood brain barrier, as agents for retarding the oxidative stress and Parkinson's disease is envisaged.
近期关于帕金森病化学病理学的研究表明,黑质中铁和脂质过氧化选择性增加,谷胱甘肽(GSH)氧化能力下降。这些变化表明存在氧化应激,可能是由于铁在黑质中蓄积所致。正是黑色素化的多巴胺能神经元易发生变性。铁与多巴胺黑色素相互作用的研究表明,多巴胺黑色素上存在两个对59Fe3+亲和力相对较高的结合位点。与Fe3+单独诱导的脂质过氧化相比,Fe3+与多巴胺黑色素的相互作用会增强大鼠大脑皮质的脂质过氧化。只有具有螯合铁能力的化合物才能抑制Fe3+与黑色素的结合以及由此产生的脂质过氧化。设想使用具有穿越血脑屏障能力的铁螯合剂作为延缓氧化应激和帕金森病的药物进行治疗。